Bank of America Merrill Lynch Form 38.5 (a) - AbbVie Inc

Date : 14/02/2020 @ 11:35
Source : UK Regulatory (RNS & others)

Bank of America Merrill Lynch Form 38.5 (a) - AbbVie Inc

TIDMTTM

RNS Number : 0824D

Bank of America Merrill Lynch

14 February 2020

FORM 38.5(a)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED

INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

 
1.  KEY INFORMATION 
 
 
 Name of exempt principal trader:            Merrill Lynch International 
 Company dealt in                            AbbVie Inc 
                                            ---------------------------- 
 Class of relevant security to which the     Common - US00287Y1091 
   dealings being disclosed relate(Note 1) 
                                            ---------------------------- 
 Date of dealing                             13/02/2020 
                                            ---------------------------- 
 
 
2.  DEALINGS (Note 2) 
 
 
(a)  Purchases and sales 
 
 
Total number of relevant securities acquired  Highest price paid (Note 3)  Lowest price paid (Note 3) 
5,016                                         95.35 USD                    95.35 USD 
                                              ---------------------------  -------------------------- 
 
 
 Total number of securities disposed   Highest price received (Note 3)   Lowest price received (Note 3) 
 N/A                                   N/A                               N/A 
                                      --------------------------------  ------------------------------- 
 
 
(b)  Derivatives transactions (other than options transactions) 
 
 
 Product name,   Nature of transaction         Number of relevant securities   Price per unit 
  e.g. CFD        (Note 4)                      (Note 5)                        (Note 3) 
     Swaps       Increasing a Short Position              10,727                 95.35 USD 
                ----------------------------  ------------------------------  --------------- 
     Swaps        Reducing a Short Position                 324                  95.476 USD 
                ----------------------------  ------------------------------  --------------- 
 
 
(c)  Options transactions in respect of existing relevant 
      securities 
 
 
(i)  Writing, selling, purchasing or varying 
 
 
  Product       Writing,       Number of      Exercise        Type,        Expiry date    Option money paid/ received 
    name,       selling,       securities       price     e.g. American,                       per unit (Note 3) 
  e.g. call    purchasing,      to which                     European 
   option        varying       the option                      etc 
                  etc.        relates (Note 
                                   5) 
    N/A           N/A             N/A           N/A            N/A             N/A                    N/A 
             -------------  ---------------  ---------  ----------------  ------------  ------------------------------ 
 
 
(ii)  Exercising 
 
 
  Product name,        Number of securities    Exercise price per 
   e.g. call option                             unit (Note 3) 
        N/A                    N/A                    N/A 
                     ----------------------  -------------------- 
 
 
3.  OTHER INFORMATION 
 
 
Agreements, arrangements or understandings relating 
 to options or derivatives 
 
 
 Full details of any agreement, arrangement or understanding between the person 
  disclosing and any other person relating to the voting rights of any relevant 
  securities under any option referred to on this form or relating to the voting rights 
  or future acquisition or disposal of any relevant securities to which any derivative 
  referred to on this form is referenced. If none, this should be stated. 
 None 
 
 
 
 Date of disclosure              14/02/2020 
 Contact name                    Tolu Tade 
                                ------------------------ 
 Telephone number                +44207 996 3410 
                                ------------------------ 
 Name of offeree/offerer with    AbbVie Inc 
  which connected 
                                ------------------------ 
 Nature of connection(Note 6)    Advisor to - AbbVie Inc 
                                ------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ISEFZLFFBLLXBBF

(END) Dow Jones Newswires

February 14, 2020 06:35 ET (11:35 GMT)

Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200217 12:42:28